Literature DB >> 15774933

Topically administered timolol and dorzolamide reduce intraocular pressure and protect retinal ganglion cells in a rat experimental glaucoma model.

M Seki1, T Tanaka, H Matsuda, T Togano, K Hashimoto, J Ueda, T Fukuchi, H Abe.   

Abstract

AIMS: This study sought to elucidate the effects of timolol and dorzolamide on intraocular pressure (IOP) and retinal ganglion cell (RGC) death in an experimental model of glaucoma in rat.
METHODS: Mild elevation of IOP was induced in rats by intracameral injection of India ink and subsequent laser trabecular photocoagulation. IOP was measured before the surgical procedures and weekly thereafter. Timolol (0.5%), timolol XE (0.5%), dorzolamide (1%), and artificial tears (vehicle) were topically applied daily. Retinal sections were prepared for histology to determine RGC number.
RESULTS: Timolol, timolol XE, and dorzolamide induced a significant reduction in IOP (p<0.05) and counteracted the reduction in RGC number that occurred in vehicle treated glaucomatous eyes (p<0.05). The coefficient of correlation between RGC number and IOP was significant in the dorzolamide treated group (r = -0.908, p<0.005), but not in other groups (p>0.05).
CONCLUSIONS: Both timolol formulation and dorzolamide reduced IOP and protected RGCs in a rat model of experimental glaucoma. It cannot be ruled out that timolol might protect RGCs by additional mechanisms other than simply lowering of IOP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15774933      PMCID: PMC1772601          DOI: 10.1136/bjo.2004.052860

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  20 in total

1.  Protective effects of timolol against the neuronal damage induced by glutamate and ischemia in the rat retina.

Authors:  Wakana Goto; Takashi Ota; Nobuo Morikawa; Yasumasa Otori; Hideaki Hara; Kouichi Kawazu; Nobuaki Miyawaki; Yasuo Tano
Journal:  Brain Res       Date:  2002-12-20       Impact factor: 3.252

2.  The beta-adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol.

Authors:  J P M Wood; K-G Schmidt; J Melena; G Chidlow; H Allmeier; N N Osborne
Journal:  Exp Eye Res       Date:  2003-04       Impact factor: 3.467

Review 3.  Retinal ganglion cells and neuroprotection for glaucoma.

Authors:  Leonard A Levin
Journal:  Surv Ophthalmol       Date:  2003-04       Impact factor: 6.048

4.  Topically applied betaxolol attenuates ischaemia-induced effects to the rat retina and stimulates BDNF mRNA.

Authors:  J P Wood; L DeSantis; H M Chao; N N Osborne
Journal:  Exp Eye Res       Date:  2001-01       Impact factor: 3.467

5.  The combined effect of brain-derived neurotrophic factor and a free radical scavenger in experimental glaucoma.

Authors:  M L Ko; D N Hu; R Ritch; S C Sharma
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-09       Impact factor: 4.799

6.  Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model.

Authors:  Yoko Ishii; Jacky M K Kwong; Joseph Caprioli
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-05       Impact factor: 4.799

Review 7.  Relationship between intraocular pressure and preservation of visual field in glaucoma.

Authors:  Ivan Goldberg
Journal:  Surv Ophthalmol       Date:  2003-04       Impact factor: 6.048

8.  Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model.

Authors:  Frank Schuettauf; Kristine Quinto; Rita Naskar; David Zurakowski
Journal:  Vision Res       Date:  2002-09       Impact factor: 1.886

Review 9.  Neuronal death in glaucoma.

Authors:  H A Quigley
Journal:  Prog Retin Eye Res       Date:  1999-01       Impact factor: 21.198

10.  BDNF is upregulated by postnatal development and visual experience: quantitative and immunohistochemical analyses of BDNF in the rat retina.

Authors:  Masaaki Seki; Hiroyuki Nawa; Takeo Fukuchi; Haruki Abe; Nobuyuki Takei
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-07       Impact factor: 4.799

View more
  10 in total

1.  Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action.

Authors:  Grace C Shih; David J Calkins
Journal:  Expert Rev Ophthalmol       Date:  2012-04

Review 2.  Pharmacotherapy of glaucoma.

Authors:  Doreen Schmidl; Leopold Schmetterer; Gerhard Garhöfer; Alina Popa-Cherecheanu
Journal:  J Ocul Pharmacol Ther       Date:  2015-01-14       Impact factor: 2.671

3.  Longitudinal outcomes of circumlimbal suture model-induced chronic ocular hypertension in Sprague-Dawley albino rats.

Authors:  Yamunadevi Lakshmanan; Francisca Siu Yin Wong; Bing Zuo; Bang Viet Bui; Henry Ho-Lung Chan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-07-05       Impact factor: 3.117

Review 4.  Pharmacological neuroprotection for glaucoma.

Authors:  Glyn Chidlow; John P M Wood; Robert J Casson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Adenosine A2A receptor mediated protective effect of 2-(6-cyano-1-hexyn-1-yl)adenosine on retinal ischaemia/reperfusion damage in rats.

Authors:  T Konno; A Sato; T Uchibori; A Nagai; K Kogi; N Nakahata
Journal:  Br J Ophthalmol       Date:  2006-04-13       Impact factor: 4.638

6.  Intraocular pressure fluctuation and neurodegeneration in the diabetic rat retina.

Authors:  Kyoung In Jung; Jung Eun Woo; Chan Kee Park
Journal:  Br J Pharmacol       Date:  2020-04-15       Impact factor: 8.739

Review 7.  Neuroprotection in glaucoma.

Authors:  Sushil K Vasudevan; Viney Gupta; Jonathan G Crowston
Journal:  Indian J Ophthalmol       Date:  2011-01       Impact factor: 1.848

Review 8.  Neuroprotection in glaucoma.

Authors:  C R Vishwaraj; Srinivasan Kavitha; Rengaraj Venkatesh; Aakriti Garg Shukla; Premanand Chandran; Shweta Tripathi
Journal:  Indian J Ophthalmol       Date:  2022-02       Impact factor: 2.969

9.  Application of Cornelian Cherry Iridoid-Polyphenolic Fraction and Loganic Acid to Reduce Intraocular Pressure.

Authors:  Dorota Szumny; Tomasz Sozański; Alicja Z Kucharska; Wojciech Dziewiszek; Narcyz Piórecki; Jan Magdalan; Ewa Chlebda-Sieragowska; Robert Kupczynski; Adam Szeląg; Antoni Szumny
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-01       Impact factor: 2.629

10.  Establishment of an experimental ferret ocular hypertension model for the analysis of central visual pathway damage.

Authors:  Takashi Fujishiro; Hiroshi Kawasaki; Makoto Aihara; Tadashiro Saeki; Reiko Ymagishi; Takuya Atarashi; Chihiro Mayama; Makoto Araie
Journal:  Sci Rep       Date:  2014-10-13       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.